Ziprasidone

Generic Name
Ziprasidone
Brand Names
Geodon, Zeldox
Drug Type
Small Molecule
Chemical Formula
C21H21ClN4OS
CAS Number
146939-27-7
Unique Ingredient Identifier
6UKA5VEJ6X
Background

Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior. These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. Luckily, several treatment options for psychotic disorders have been ...

Indication

In its oral form, ziprasidone is approved for the treatment of schizophrenia, as monotherapy for acute treatment of manic or mixed episodes related to bipolar I disorder, and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder. The injectable formulation is approved only for treatment of acute agitation in schizophre...

Associated Conditions
Acute Agitation, Agitation, Bipolar 1 Disorder, Psychosis, Schizophrenia, Treatment Resistant Major Depressive Disorder, Acute Manic episode, Acute Mixed manic depressive episode
Associated Therapies
-
Clinical Trials
Related News

Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus

Phase 4
Completed
Conditions
Schizophrenia
First Posted Date
2006-07-12
Last Posted Date
2017-01-13
Lead Sponsor
North Suffolk Mental Health Association
Target Recruit Count
24
Registration Number
NCT00351000
Locations
🇺🇸

Freedom Trail Clinic, Boston, Massachusetts, United States

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

First Posted Date
2006-07-04
Last Posted Date
2008-05-21
Lead Sponsor
Solvay Pharmaceuticals
Target Recruit Count
286
Registration Number
NCT00347425
Locations
🇺🇸

Site 180, Kenilworth, New Jersey, United States

🇦🇷

Site 308, Mendoza, Argentina

🇭🇺

Site 212, Gyor, Hungary

and more 119 locations

Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression

First Posted Date
2006-06-21
Last Posted Date
2014-08-19
Lead Sponsor
Duke University
Target Recruit Count
72
Registration Number
NCT00340379
Locations
🇺🇸

University of Southern California, Los Angeles, California, United States

🇪🇬

Alexandria University, Alexandria, Egypt

🇮🇳

National Institute of Mental Health and Neuroscience, Bangalore, India

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

First Posted Date
2006-05-29
Last Posted Date
2018-07-10
Lead Sponsor
Northwell Health
Target Recruit Count
357
Registration Number
NCT00330863
Locations
🇺🇸

University of California, Los Angeles, Los Angeles, California, United States

🇺🇸

Medical College of Georgia, Department of Psychiatry, Augusta, Georgia, United States

🇺🇸

Harvard Medical School -- Dr. John C. Corrigan Community Mental Health Center, Fall River, Massachusetts, United States

and more 5 locations

3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects

Phase 3
Completed
Conditions
Bipolar Disorder
Interventions
Drug: Placebo
Drug: Ziprasidone
First Posted Date
2006-04-10
Last Posted Date
2021-03-29
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
680
Registration Number
NCT00312494
Locations
🇺🇸

Pfizer Investigational Site, Kirkland, Washington, United States

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

First Posted Date
2005-11-15
Last Posted Date
2024-12-13
Lead Sponsor
Vanda Pharmaceuticals
Target Recruit Count
593
Registration Number
NCT00254202
Locations
🇮🇳

Vanda Investigational Site, Chinawaltair, Visakha Patnam, India

🇮🇳

Vanda Investgational Site, Chennai, Tamilnadu, India

Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia.

Phase 4
Completed
Conditions
Schizophrenia
First Posted Date
2005-10-14
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
112
Registration Number
NCT00239109
Locations
🇪🇸

Pfizer Investigational Site, Zamora, Spain

Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression

First Posted Date
2005-10-12
Last Posted Date
2013-06-19
Lead Sponsor
The Medical Research Network
Target Recruit Count
30
Registration Number
NCT00237666
Locations
🇺🇸

Medical Research Network, L.L.C., New York, New York, United States

🇺🇸

The Mech Center, Plano, Texas, United States

Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)

Not Applicable
Completed
Conditions
Schizophrenia
Obsessive Compulsive Disorder
Interventions
Drug: Ziprasidone
First Posted Date
2005-09-29
Last Posted Date
2013-12-31
Lead Sponsor
Sheba Medical Center
Target Recruit Count
45
Registration Number
NCT00229385
Locations
🇮🇱

Chaim Sheba Medical Center, Ramat-Gan, Israel

Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial

Phase 4
Completed
Conditions
Schizophrenia, Schizoaffective Disorder
First Posted Date
2005-09-22
Last Posted Date
2008-06-04
Lead Sponsor
Central Institute of Mental Health, Mannheim
Target Recruit Count
24
Registration Number
NCT00224315
Locations
🇩🇪

Central Institute of Mental Health, Department of Psychiatry,, Mannheim, BW, Germany

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy